Ultragenyx Pharmaceutical Inc. Common Stock RARE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-10T22:23:19.099Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:02:38.121666244Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-10T22:23:18.606087+00:00
Ultragenyx Pharmaceutical Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 15.68 | 93.3% | 5.0% | |||
| 40Δ | 15.86 | 91.6% | 4.2% | |||
| 45Δ | 16.33 | 78.7% | 3.6% | 16.03 | 89.2% | 3.5% |
| 50Δ | 16.18 | 80.0% | 3.1% | 16.17 | 84.1% | 3.0% |
| 55Δ | 16.04 | 81.2% | 2.7% | 16.31 | 78.9% | 2.4% |
| 60Δ | 15.89 | 80.1% | 2.2% | |||
| 65Δ | 15.75 | 78.2% | 1.8% | 17.26 | 162.2% | 3.2% |
| 70Δ | 15.61 | 76.2% | 1.4% | 17.51 | 151.2% | 2.4% |
| 75Δ | 17.91 | 153.4% | 1.9% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.68
- IV
- 93.3%
- B/E move
- 5.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.86
- IV
- 91.6%
- B/E move
- 4.2%
45Δ
- Pseudo strike
- 16.33
- IV
- 78.7%
- B/E move
- 3.6%
- Pseudo strike
- 16.03
- IV
- 89.2%
- B/E move
- 3.5%
50Δ
- Pseudo strike
- 16.18
- IV
- 80.0%
- B/E move
- 3.1%
- Pseudo strike
- 16.17
- IV
- 84.1%
- B/E move
- 3.0%
55Δ
- Pseudo strike
- 16.04
- IV
- 81.2%
- B/E move
- 2.7%
- Pseudo strike
- 16.31
- IV
- 78.9%
- B/E move
- 2.4%
60Δ
- Pseudo strike
- 15.89
- IV
- 80.1%
- B/E move
- 2.2%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 15.75
- IV
- 78.2%
- B/E move
- 1.8%
- Pseudo strike
- 17.26
- IV
- 162.2%
- B/E move
- 3.2%
70Δ
- Pseudo strike
- 15.61
- IV
- 76.2%
- B/E move
- 1.4%
- Pseudo strike
- 17.51
- IV
- 151.2%
- B/E move
- 2.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.91
- IV
- 153.4%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 124.45% | |
| 138.03% | |
| 132.56% | |
| 130.65% | |
| 136.60% | |
| 152.95% | |
| 134.86% | |
| 135.56% | |
| 136.42% | |
| 138.21% | |
| 137.64% | |
| 144.77% | |
| 150.76% | |
| 150.24% | |
| 155.69% | |
| 67.78% | |
| 62.58% | |
| 65.88% | |
| 105.59% | |
| 66.85% | |
| 64.65% | |
| 62.12% | |
| 63.67% | |
| 87.04% | |
| 67.98% | |
| 75.85% | |
| 82.27% | |
| 86.00% | |
| 139.08% | |
| 90.89% | |
| 78.73% | |
| 72.44% | |
| 70.19% | |
| 121.59% | |
| 62.34% | |
| 70.18% | |
| 68.05% | |
| 78.45% | |
| 130.11% | |
| 82.71% | |
| 95.73% | |
| 71.83% | |
| 63.50% | |
| 83.21% | |
| 74.28% | |
| 82.17% | |
| 85.34% | |
| 113.23% | |
| 81.96% | |
| 73.00% |
Biotechnology
RCKT
Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company is…
More →RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward,…
More →REGN
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their…
More →REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
More →RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body…
More →RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is…
More →